ArriVent BioPharma

US · AVBP #3057 by market cap Listed 2024

16.89 +1.80 +11.93%

Live - 5344 symbols - heartbeat 252s ago · 2026-10-08 06:32

Pre-market 16.70 -1.12%

After-hours 17.10 +1.24%

Overnight 16.89 0.00%

Market cap: 832.81M
P/E (TTM): -4.76
P/B: 2.27
EPS: -4.32
Div yield: 0.00%
52W pos: 23%

Reader sentiment Are you bullish or bearish on AVBP?

Anonymous reader poll. Unscientific, not investment advice.

About ArriVent BioPharma

Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, licensing, and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company was founded Zheng Bin Yao and Stuart Lutzker on April 14, 2021 and is headquartered in Newtown Square, PA.

Founded: 2021
CEO: Dr. Zhengbin Yao, PhD
Employees: 77
Headquarters: Newtown Square, Pennsylvania, United States of America
Fiscal year end: 12-31
Website: arrivent.com

Company profile

Exchange: US
Symbol: AVBP
Market-cap rank: #3057
Listing date: 2024-01-26
Market cap: 832.81M
Float cap: 542.27M
Shares out: 49.31M
Float shares: 32.11M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 06:32:29 · For reference only, not investment advice and not tailored to your situation.